Adults with type 1 diabetes may benefit from adjunctive treatment with liraglutide to improve glycaemic control and other risk factors for diabetes-related complications. The American Diabetes Association’s 78th Scientific Sessions heard the results of a 52-week randomised controlled trial of daily liraglutide (1.8 mg) versus placebo as an adjunct to insulin therapy. Patients in the ...
Type 1 diabetes
GLP-1 agonist a useful adjunct to insulin therapy in type 1 diabetes
By Mardi Chapman
10 Jul 2018